East Windsor, NJ (MAY 19, 2015) – In a recent clinical trial published in the Iranian Journal of Pharmaceutical Research 2015, Sabinsa’s Curcumin C3 Complex® showed promising results in reducing the serum levels of triglycerides, LDL cholesterol and VLDL cholesterol in subjects with coronary artery disease (CAD).
This randomized double blind placebo controlled clinical study was conducted at the Tehran Heart Center Hospital, Iran, between December 2011 – Feb 2013. Scientists and clinicians associated with the Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences (Tehran, Iran), Pharmaceutical Research Center, Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, (Mashhad, Iran) and Tehran Heart Center, School of Medicine, Tehran University of Medical Sciences (Tehran, Iran) conducted the clinical trial.
CAD is one of the most common types of heart disease and is the leading causes of death in the United States. In this eight week study, 33 subjects with coronary artery disease were recruited. The subjects were administered 4 capsules of 500mg of Curcumin C3 Complex® each per day or matching placebo for two months in addition to conventional therapies. Blood samples were withdrawn at baseline and at the end of the study. The results revealed that Curcumin supplementation significantly reduced the serum levels of LDL and triglycerides compared to the baseline. This study also showed a significant decrease in the VLDL values in the Curcumin group.
The authors of study concluded that Curcumin seems to be a potential candidate for decreasing cholesterol and triglycerides levels. The findings of the present study requisites a larger clinical trial, which can assess the metabolic and anti-inflammatory effect of Curcumin supplementation on people suffering from cardiovascular disease.
For more information, visit www.sabinsa.com and www.curcuminoids.com.
